Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.
BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...
Debi Weiss thought her fatigue and weakness was a seasonal illness, but her condition quickly worsened.
Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...
A fasting-derived ketone metabolite reshapes CAR T cell metabolism and gene activity, boosting immune cell expansion, energy ...
Detailed price information for Citius Pharmaceuticals Inc (CTXR-Q) from The Globe and Mail including charting and trades.
In August 2025, Edd Vieira, an engineer from Northamptonshire, England, was on vacation visiting his family in Portugal when ...
The Kathmandu Post on MSN
Nepal approves first domestically produced CAR T-cell therapy
Kathmandu, March 7 -- Nepal has approved its first domestically manufactured CAR T-cell therapy for clinical use, marking a milestone in the country's cancer treatment capabilities. The Department of ...
5d
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Lyell Immunopharma, Inc. ( LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST ...
Detailed price information for Citius Oncology Inc (CTOR-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results